For Members
EMIG members' medical industry knowledge must be current in a landscape that is constantly changing. Through the EMIG platform, our online and in-person events, members can network and exchange information.
What is the EMIG platform?
Our exclusive platform enhances your membership with a personalised dashboard that provides easy access to:
Network
Submit questions or requests anonymously to the Network and receive curated responses, or search the directory for previously asked questions
Events
View and register for upcoming events by interest group, track your personal event schedule, and join live sessions directly through the platform
Resources
Quick access to documents, videos, and podcasts
Featured Network Questions
Tap into the collective expertise of the EMIG network. Browse recent questions and curated responses, or submit your own inquiries to connect with industry peers.
We are launching an ERT that requires fridge storage. We have been asked by hospitals to provide patients with a fridge to store drug for self administration at home.
I am helping an organisation looking at their internship programme(s) for next year and would value input please.
We are looking for a warehouse company where we can stock and distribute stock and samples for our field team
Does anyone have any experience of submitting a MAA via the IRP route for a new biotechnology product?
Featured Events
Below are upcoming events that may be relevant to EMIG members, register your attendance now.
Where to start on sustainability?
Zoom WebinarHosted by: ExternalAgenda: Join us for the first in a series of four interactive, invite-only roundtables designed specifically for pharma decision-makers and professionals who want to deepen their sustainability impact. This meeting is being organised by the law firm, VWV and so any queries should be addressed to them. Contact details are on the registration page.
EMIG Quarterly Meeting
London
Hosted by: EMIGAgenda: A varied agenda, featuring the VPAG negotiations, NHS 10 Year Plan Update + ICB/commissioning/NHSE Update, Government Policy update and a panel session with a health system expert panel discussing NHS the NHS 10-year plan, balancing the present with the future, and the realities for life sciences.
EMIG Women in Pharma Webinar
Zoom WebinarHosted by: EMIGAgenda: Our guest speaker, Hannah Collison will be speaking about Resilience, what it is and what can we do to develop our own resilience.
EMIG Wales Webinar
Zoom WebinarHosted by: EMIGAgenda: Power Shift: Why Election ’26 Will Bring New Risks and Opportunities for Organisations in Wales. The presentation explores the significant political change with the election of a new Welsh Parliament with more members, elected under a different electoral process, what it means for the political parties, and the shape of the next Welsh Government.
Featured Resources
Our resources library offers easy access to useful materials including presentations, documents, videos and podcasts. The resources are organised by most recent date upload but you can sort, filter and search by the name of the event, category or file type.
Government
Richard Williams' September Newsletter
NICE
NICE's new drug approval removal policy
Special Interest Groups
We have 14 SIGs which reflect the myriad demands on the professionals that are vital to a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG members' views on a wide range of issues, from regulation and research to pricing and orphan diseases.
Each group has a chair, and determines the content of each meeting agenda.
EMIG is represented on the following:
DHSC
The Department of Health & Social Care in London is a ministerial department responsible, inter alia, for England's NHS, the health of the nation and access to medicines. EMIG works closely with the Department on issues such as medicines supply and pricing.MHRA
The Medicines and Healthcare Regulatory Authority is responsible to the DHSC for ensuring that medicines and medical devices in the UK work and are acceptably safe. EMIG works closely with the MHRA, HTA agencies and the NHS to ensure the prompt availability of new medicines to patients.AWTTC
The All Wales Therapeutics and Toxicology Centre advise on new medicines to ensure they are used effectively and appropriately in Wales and EMIG has a seat on the AWTTC Committee.EUCOPE
The European Confederation of Pharmaceutical Entrepreneurs has been the voice of small and mid-sized pharmaceutical and biotech companies in Europe for the last 15 years. EMIG has been part of EUCOPE from the outset and Leslie Galloway is Vice president of the Board.
Our Priorities
A healthy life sciences sector
- 1Driving the opportunities that the VPAG agreement offers the NHS
- 2Supporting a vibrant research community
- 3Expanding a large and highly skilled manufacturing sector
- 4A concentration of leadership and commercial expertise
- 5Ensuring a flexible and supportive licensing and reimbursement process
- 6A sophisticated and world-beating life sciences support services sector
- 7A connected regulatory, HTA and reimbursement process to accelerate patient access
Support the rebuild of the UK and NHS
- Illustrate the benefits of the VPAG Agreement £400m Industry Investment Facility to stakeholders
- Persuade global decision makers to invest in the UK
- Ensure innovative medicines reach UK patients
- Demonstrate how the implementation of the VPAG can support NHS affordability
Enable
...a vibrant research and development community through advocating for the creation of a life sciences sector research collaborative.
Encourage
...the building of a large and highly skilled manufacturing sector by pressing for capital investment allowances and tax credits at competitive levels.
Develop
...a concentration of commercial expertise and encourage global pharmaceutical HQs to locate their commercial centres in the UK.
Accelerate
...patient access to innovative medicines by developing marketing authorisation and health technology assessment in parallel, where companies opt to do so.
Leverage
...the life science sector's support services of the future through the UK's reputation for world-leading HTA assessment.